Display options
Cite
Song J, Dagan A, Yakhtin Z, et al. The novel sphingosine-1-phosphate receptors antagonist AD2900 affects lymphocyte activation and inhibits T-cell entry into the lymph nodes. Oncotarget. 2017;8(32):53563-53580doi: 10.18632/oncotarget.18626.
Song, J., Dagan, A., Yakhtin, Z., Gatt, S., Riley, S., Rosen, H., Or, R., & Almogi-Hazan, O. (2017). The novel sphingosine-1-phosphate receptors antagonist AD2900 affects lymphocyte activation and inhibits T-cell entry into the lymph nodes. Oncotarget, 8(32), 53563-53580. https://doi.org/10.18632/oncotarget.18626
Song, Jing, et al. "The novel sphingosine-1-phosphate receptors antagonist AD2900 affects lymphocyte activation and inhibits T-cell entry into the lymph nodes." Oncotarget vol. 8,32 (2017): 53563-53580. doi: https://doi.org/10.18632/oncotarget.18626
Song J, Dagan A, Yakhtin Z, Gatt S, Riley S, Rosen H, Or R, Almogi-Hazan O. The novel sphingosine-1-phosphate receptors antagonist AD2900 affects lymphocyte activation and inhibits T-cell entry into the lymph nodes. Oncotarget. 2017 Jun 27;8(32):53563-53580. doi: 10.18632/oncotarget.18626. eCollection 2017 Aug 08. PMID: 28881832; PMCID: PMC5581131.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jun 27;8(32):53563-53580. doi: 10.18632/oncotarget.18626. eCollection 2017 Aug 08.

The novel sphingosine-1-phosphate receptors antagonist AD2900 affects lymphocyte activation and inhibits T-cell entry into the lymph nodes.

Oncotarget

Jing Song, Arie Dagan, Zhanna Yakhtin, Shimon Gatt, Sean Riley, Hugh Rosen, Reuven Or, Osnat Almogi-Hazan

Affiliations

  1. Department of Bone Marrow Transplantation, Hebrew University-Hadassah School of Medicine, Jerusalem, Israel.
  2. Department of Biochemistry and Molecular Biology, Hebrew University-Hadassah School of Medicine, Jerusalem, Israel.
  3. Department of Chemical Physiology, The Scripps Research Institute, California, USA.

PMID: 28881832 PMCID: PMC5581131 DOI: 10.18632/oncotarget.18626

Abstract

Sphingolipid derivatives play key roles in immune cell migration and function. Synthetic sphingolipid analogues are used as therapeutics to intervene various inflammatory and malignant conditions. We hypothesize that different analogs have different effects on immune cells and therefore can be used as treatment for specific diseases. This study examines the properties of the novel synthetic sphingolipid analog, AD2900, and its effects on immune cell activation and lymphocyte localization in homeostasis. AD2900 is an antagonist for all sphingosine-1-phosphate (S1P) receptors. It demonstrates a significant inhibitory effect on the proliferation of activated human peripheral blood mononuclear cells, which is dependent on cAMP reduction and calcium signal transduction but not on phospholipase C activation. AD2900 causes a significant but reversible downregulation of S1P1 expression on the cell surface. AD2900 administration to C57BL/6J mice leads to the accumulation of T cells in the blood and spleen and in turn reduces T-cell number in the lymph nodes. Moreover, AD2900 treatment shows significant effects on the localization of T-cell subpopulations. These results demonstrate the key roles of S1P in T-cell trafficking in a steady state and suggest a potential clinical application for AD2900. Notably, this sphingolipid analog does not cause a severe lymphopenia. The clinical effect of AD2900 in hemato-oncologic diseases and immune-related diseases needs further investigation.

Keywords: S1PR; T cells; lymphocyte activation; lymphocyte localization; sphingosine-1-phosphate

Conflict of interest statement

CONFLICTS OF INTEREST Prof. Shimon Gatt and Dr. Arie Dagan hold a patent on AD2900. Dr. Jing Song, Mrs. Zhanna Yakhtin, Dr. Sean Riley, Prof. Hugh Rosen, Prof. Reuven Or, and Dr. Osnat Almogi-Hazan de

References

  1. Transpl Immunol. 2006 Apr;15(4):281-8 - PubMed
  2. Immunology. 1998 Dec;95(4):591-4 - PubMed
  3. BMC Cancer. 2014 Dec 03;14:911 - PubMed
  4. Science. 2002 Apr 12;296(5566):346-9 - PubMed
  5. Br J Pharmacol. 2009 Nov;158(5):1173-82 - PubMed
  6. Nat Immunol. 2007 Dec;8(12):1295-301 - PubMed
  7. Immunity. 2013 Nov 14;39(5):806-18 - PubMed
  8. Science. 2007 Apr 13;316(5822):295-8 - PubMed
  9. Nature. 2013 Jan 31;493(7434):684-8 - PubMed
  10. J Lipid Res. 2005 Nov;46(11):2315-24 - PubMed
  11. J Exp Med. 2016 Nov 14;213(12 ):2773-2791 - PubMed
  12. Nat Immunol. 2007 Dec;8(12):1337-44 - PubMed
  13. J Cancer Res Ther. 2013 Oct-Dec;9(4):556-63 - PubMed
  14. Nat Chem Biol. 2010 Jul;6(7):489-97 - PubMed
  15. Cancer Res. 2005 Dec 15;65(24):11667-75 - PubMed
  16. Mol Pharmacol. 2013 Feb;83(2):316-21 - PubMed
  17. Nat Rev Immunol. 2014 Jan;14(1):24-35 - PubMed
  18. J Biol Chem. 2002 Jun 14;277(24):21197-206 - PubMed
  19. Int Immunopharmacol. 2011 Nov;11(11):1773-9 - PubMed
  20. PLoS One. 2016 Jan 29;11(1):e0148137 - PubMed
  21. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6585-7 - PubMed
  22. Clin Neuropharmacol. 2010 Mar-Apr;33(2):91-101 - PubMed
  23. J Immunol. 2005 Feb 15;174(4):1997-2003 - PubMed
  24. J Immunol. 2005 Sep 1;175(5):2913-24 - PubMed
  25. Front Immunol. 2012 Feb 27;3:23 - PubMed
  26. J Exp Med. 1999 Feb 1;189(3):451-60 - PubMed
  27. Biochim Biophys Acta. 2008 Sep;1781(9):477-82 - PubMed
  28. J Immunol. 2003 Oct 1;171(7):3500-7 - PubMed
  29. J Exp Med. 2009 Oct 26;206(11):2469-81 - PubMed
  30. J Immunol. 2005 Mar 1;174(5):2485-8 - PubMed
  31. Nat Immunol. 2005 Sep;6(9):895-901 - PubMed
  32. J Exp Med. 2005 Jan 17;201(2):291-301 - PubMed
  33. J Immunol. 2011 Mar 15;186(6):3432-40 - PubMed
  34. J Biol Chem. 2007 Mar 23;282(12 ):9082-9 - PubMed
  35. Br J Cancer. 2012 Feb 28;106(5):909-15 - PubMed
  36. Annu Rev Immunol. 2009;27:591-619 - PubMed
  37. Immunity. 2008 Jan;28(1):122-33 - PubMed
  38. Eur J Immunol. 2000 May;30(5):1435-44 - PubMed
  39. Biochim Biophys Acta. 2003 Sep 22;1633(3):161-9 - PubMed
  40. Mol Cell Biol. 2006 Oct;26(19):7211-23 - PubMed
  41. Cell. 1999 Oct 1;99(1):23-33 - PubMed
  42. J Neurochem. 2007 Aug;102(4):1151-61 - PubMed
  43. Nat Rev Immunol. 2013 May;13(5):309-20 - PubMed
  44. J Cell Biochem. 2004 Aug 1;92(5):937-48 - PubMed
  45. Science. 2010 May 28;328(5982):1129-35 - PubMed
  46. Blood. 2008 Aug 15;112(4):1129-38 - PubMed
  47. Med Res Rev. 2017 Jan;37(1):3-51 - PubMed
  48. J Immunol. 2012 Jan 1;188(1):206-15 - PubMed
  49. Clin Ther. 2015 Apr 1;37(4):691-715 - PubMed
  50. J Biol Chem. 1998 Oct 16;273(42):27104-10 - PubMed
  51. Nature. 1999 Oct 14;401(6754):708-12 - PubMed
  52. Nat Immunol. 2005 Sep;6(9):889-94 - PubMed
  53. Nat Immunol. 2004 Jul;5(7):713-20 - PubMed
  54. Science. 2005 Sep 9;309(5741):1735-9 - PubMed
  55. Cancer Invest. 2010 Jun;28(5):535-43 - PubMed
  56. Chem Biol. 2012 Sep 21;19(9):1142-51 - PubMed
  57. J Biol Chem. 2004 Apr 9;279(15):15396-401 - PubMed
  58. ACS Chem Biol. 2008 Aug 15;3(8):486-98 - PubMed
  59. Pharmacol Ther. 2007 Jul;115(1):84-105 - PubMed
  60. Nature. 2004 Jan 22;427(6972):355-60 - PubMed
  61. Eur J Immunol. 2012 Aug;42(8):1949-55 - PubMed
  62. J Biol Chem. 2002 Jun 14;277(24):21453-7 - PubMed
  63. Annu Rev Cell Biol. 1986;2:231-53 - PubMed
  64. Cell Signal. 2003 Jul;15(7):677-87 - PubMed
  65. Nat Rev Immunol. 2008 Oct;8(10):753-63 - PubMed
  66. Anticancer Agents Med Chem. 2011 Nov;11(9):782-93 - PubMed

Publication Types

Grant support